Indian women always like to keep up with the latest trends released in blouse designs. From halter neck to anne-cut, many times we look up to Bollywood for inspiration or take on cues from the ...

You can pair these stunning blouses with your saris and lehenga and can stand out to be the talk of the crowd. From sleek pearls to stunning strappy fits, let’s take a glance at some of the best ...

Amgen’s Phase 1 data shows no association between MariTide and bone mineral density changes, supporting its safety claims. Analyst highlights that study data suggests a 4% BMD decrease at the ...

(RTTNews) - Amgen Inc. (AMGN) Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes in bone mineral density. Following the news ...

Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in the fast ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. Also Read: Jim Cramer ...

Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density ...

Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone mineral density linked to its obesity candidate MariTide, which led to a ~7% ...

The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial. Amgen published data from the study in the journal Nature Metabolism ...

THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As ...